...
首页> 外文期刊>Indian journal of pharmacology. >A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh
【24h】

A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh

机译:一项前瞻性观察队列研究,在偏远的资源受限的恰蒂斯加尔邦部落人群中引发抗逆转录病毒药物的不良反应

获取原文
获取原文并翻译 | 示例
           

摘要

Objective : To assess the adverse effects of antiretroviral therapy (HAART) and its adherence in HIV-infected patients, in remote and tribal area with restricted resources. Materials and Methods : This was a prospective, observational study carried out at Department of Medicine, Government Medical College, Jagdalpur. A set of questions were asked and adverse drug reactions (ADRs) were recorded for every patient. Results : 79 HIV positive patients were analyzed. Among them, 68 (86%) had at least one ADR. The mean ADR per patient was 1.64 (1.09). The most common ADR in our study was peripheral neuropathy (20.83%), followed by skin rashes (15.83%). Twenty-one patients (26.58%) had severe (grade-3 and grade-4) ADRs. Female patients had more ADRs (45.71%) than males (11.36%); severe ADRs had a statistically significant positive correlation with sex and CD4 cell count of the patients. Conclusion : In spite of high ADRs, HAART is the only answer to HIV/AIDS; thus, management requires a highly precise balance between benefits of durable HIV suppression and the risks of drug toxicity to achieve the therapeutic goals, with conventional drugs or with newer less toxic agents.
机译:目的:评估资源有限的偏远和部落地区抗逆转录病毒疗法(HAART)的不良反应及其依从性。材料和方法:这是在Jagdalpur政府医学院的医学系进行的前瞻性观察研究。提出了一系列问题,并记录了每位患者的药物不良反应(ADR)。结果:对79例HIV阳性患者进行了分析。其中68个(86%)拥有至少一种ADR。每位患者的平均ADR为1.64(1.09)。在我们的研究中,最常见的ADR是周围神经病变(20.83%),其次是皮疹(15.83%)。 21名患者(26.58%)患有严重(3级和4级)ADR。女性患者的ADR(45.71%)比男性(11.36%)多;严重的ADR与患者的性别和CD4细胞计数具有统计学显着的正相关。结论:尽管ADR很高,但HAART是艾滋病毒/艾滋病的唯一解决方案。因此,管理需要在使用常规药物或使用毒性较小的新型药物时,在持续抑制HIV的益处与药物毒性的风险之间达到高度精确的平衡,以达到治疗目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号